Karolina Mizeracka
0000-0002-2472-2310
Publication & Citation Trends
Most Cited Works
Publications
18 total
Abstract 1828: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies.
Cited by 0
OpenAlex
Abstract 6064: Discovery of potent and selective EP300 degraders with anti-cancer activity
Cited by 2
OpenAlex
Abstract 6067: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
Cited by 1
OpenAlex
Abstract B024: Leveraging synthetic lethality across EP300-mutant solid cancers through selective CBP degradation
Cited by 0
OpenAlex
Abstract A060: Discovery of potent and selective EP300 degraders with anti-cancer activity
Cited by 0
OpenAlex
Lineage-specific control of convergent differentiation by a Forkhead repressor PDF
Cited by 16
OpenAlex
Loss of the Extracellular Matrix Protein DIG-1 Causes Glial Fragmentation, Dendrite Breakage, and Dendrite Extension Defects PDF
Cited by 3
OpenAlex
Loss of the extracellular matrix protein DIG-1 causes glial fragmentation, dendrite breakage, and dendrite extension defects PDF
Cited by 0
OpenAlex
Research Topics
Genetics, Aging, and Longevity in Model Organisms
(4)
Retinal Development and Disorders
(4)
Histone Deacetylase Inhibitors Research
(4)
Protein Degradation and Inhibitors
(4)
Epigenetics and DNA Methylation
(3)
Frequent Co-Authors
Affiliations
Tufts University
Boston Children's Hospital
Harvard University
Boston VA Research Institute
Pediatrics and Genetics